Form D · Biotechnology
Converge Bio Inc.
Claymont, DE · CIK 0002131104
Offering snapshot reported Apr 28, 2026 · SEC filing
- Reported sold
- $25M Offering amount: $25M
- Investors reported
- 19 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 24, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 28, 2026 | Initial | $25,000,000 | No comparison | 19 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-582089
Source: Form D, filed Apr 28, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dov Gertz | Director, Executive |
| Andrew Hedin | Director |
| Oded Kalev | Director, Executive |
| Shahar Tzafrir | Director |
| Iddo Weiner | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2093 Philadelphia Pike #1664
Claymont, DE, 19703
Claymont, DE, 19703